Positive Phase 2 Interim Results from BEXMAB Trial
Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Inside Information: Faron Announces Positive Phase 2 Interim Results from BEXMAB Trial to be presented at ASH Company announcement, Inside Information, 27 November 2024 Key highlights - Interim Phase 2 read-out from the BEXMAB Trial confirms earlier positive Phase 1 & 2 findings in MDS patients with prior HMA failure - In Phases 1 & 2, 20 MDS patients who are refractory or relapsed on HMA (r/r MDS) and have no effective treatment options, continue to show high objective response